Quanterix (QTRX) investor relations material

Leadership and strategic direction

• New CEO emphasizes early stage of transformation, focusing on sustainable growth and leveraging recent Akoya acquisition for diversification beyond neurology into oncology and immunology.

• Diagnostics is a key growth driver, with a differentiated five-marker blood-based test and a 510(k) submission to the FDA; feedback expected in 6–9 months.

• A comprehensive diagnostics plan is set for release in the second half of the year, targeting significant impact from 2027 onward.

• Prioritization and focus are highlighted as essential for execution, with leadership intent on not spreading resources too thin.

Financial performance and outlook

• Achieved synergy targets from Akoya acquisition and maintains a strong balance sheet with $100 million in cash and no debt.

• Fourth quarter outperformed expectations, driven by recurring consumables revenue and academic funding recovery.

• 2026 guidance assumes 0–3% growth, reflecting a conservative approach due to market uncertainties and tough comps.

• Cost structure is right-sized post-synergies, with gross margins returning to 50% and OpEx targeted at $85 million.

Diagnostics and competitive positioning

• The diagnostics test offers a 10% indeterminate zone, outperforming competitors with higher indeterminate rates and more complex workflows.

• $897 Medicare reimbursement pricing secured, with payer engagement ongoing and clinical utility studies expected to ease future coverage discussions.

• Leadership embraces competition, viewing it as a motivator for innovation and market validation.